## Note
nid: 1517957490965
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Immunology_+_General_Pathology::Pathoma_Chapter_3_(Neoplasia), #AK_Step1_v11::!FLAG_THESE_CARDS::!DELETE, #AK_Step1_v11::#AMBOSS::#Self_Assesment, #AK_Step1_v11::#AMBOSS::Immunology, #AK_Step1_v11::#B&B::08_Endocrinology::05_Other::04_Signaling_Pathways, #AK_Step1_v11::#FirstAid::04_Pathology::03_Neoplasia::08_Oncogenes, #AK_Step1_v11::#FirstAid::04_Pathology::03_Neoplasia::08_Oncogenes::Growth_Factors::JAK, #AK_Step1_v11::#FirstAid::10_Hematology_Oncology::04_Pathology::29_Chronic_Myeloproliferative_Disorders, #AK_Step1_v11::#FirstAid::10_Hematology_Oncology::04_Pathology::29_Chronic_Myeloproliferative_Disorders::*Basics, #AK_Step1_v11::#OME::13_Hematology_Oncology::04_Proliferation::02_Myeloproliferation, #AK_Step1_v11::#OME_banner::Basic_Science::13_Hematology_Oncology::18_Myeloproliferative_Disorders, #AK_Step1_v11::#Pathoma::03_Neoplasia::02_Carcinogenesis::2_Oncogenes, #AK_Step1_v11::#Pathoma::03_Neoplasia_Alt_Tagging::BlueGalaxies::02_Carcinogenesis::2_Oncogenes, #AK_Step1_v11::#Physeo::11_Pathology::07_General_Pathology::09_Carcinogenesis, #AK_Step1_v11::#Physeo::11_Pathology::10_HemeOnc_Pathology::14_Myeloproliferative_Disorders, #AK_Step1_v11::#SketchyPath::10_Myeloid_&_Lymphoid::01_Myeloid_Disorders::01_Myeloproliferative_Neoplasms_&_Myelodysplastic_Syndromes, #AK_Step1_v11::#UWorld::1000-9999::8000-8999::8591, #AK_Step1_v11::#UWorld::10000-99999::15000-15999::15323, #AK_Step1_v11::^Other::^EXPN::BGadd, #AK_Step1_v11::^Other::^FA_Updates::FA2018
markdown: false

### Text
<div>
  Mutations in which <b>proto</b>-<b>oncogene</b> can lead to
  <u>Chronic Myeloproliferative Disorders</u>?
</div>
<div>
  <div>
    <div>
      {{c1::JAK2}}
    </div>
  </div>
</div>

### Extra
- JAK2 is a non-receptor tyrosine kinase that when mutated at the
617 position to Phenylalanine becomes exquisitely sensitive to
growth factors like EPO / TPO
<div>
  - JAK/STAT pathway is involved with lots of cytokines (ex. IL-2,
  IFN, G-CSF) and anterior pituitary hormones (ex. Prolactin, GH)
</div>
<div><img src="paste-17343077941249.jpg"></div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid


### Sketchy
<div>
  - JAK2 is a non-receptor tyrosine kinase that when mutated at the
  617 position to Phenylalanine becomes exquisitely sensitive to
  growth factors like EPO / TPO
  <div>
    - JAK/STAT pathway is involved with lots of cytokines (ex.
    IL-2, IFN, G-CSF) and anterior pituitary hormones (ex.
    Prolactin, GH)
  </div>
</div><img src="JAK%202_1566160514431.jpg"><img src=
"Myeloid%20cell%20lines.jpg"><img src=
"Zoverall%20picture-ace238e13bfd46659e36c0f90d51636a940ebb34.JPG">

### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href=
  "https://onlinemeded.org/spa/heme-onc/myeloproliferative-disorders/acquire?ref=anki">
  <img src="_OME_AnkiFlashcards_Lesson_2.png"></a>
</div>

### Additional Resources


### One by one

